Show simple item record

dc.contributor.authorVokes, Everett E.
dc.contributor.authorHerndon, James E. 2nd
dc.contributor.authorKelley, Michael J.
dc.contributor.authorCicchetti, Maria Giulia
dc.contributor.authorRamnath, Nithya
dc.contributor.authorNeill, Harvey
dc.contributor.authorAtkins, James N.
dc.contributor.authorWatson, Dorothy M.
dc.contributor.authorAkerley, Wallace
dc.contributor.authorGreen, Mark R.
dc.date2022-08-11T08:10:46.000
dc.date.accessioned2022-08-23T17:18:56Z
dc.date.available2022-08-23T17:18:56Z
dc.date.issued2007-05-01
dc.date.submitted2015-05-07
dc.identifier.citationVokes EE, Herndon JE 2nd, Kelley MJ, Cicchetti MG, Ramnath N, Neill H, Atkins JN, Watson DM, Akerley W, Green MR; Cancer and Leukemia Group B. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol. 2007 May 1;25(13):1698-704. Epub 2007 Apr 2. PubMed PMID: 17404369. <a href="http://dx.doi.org/10.1200/JCO.2006.07.3569">Link to article on publisher's site</a>. Epub 2007 Apr 2.
dc.identifier.issn0732-183X (Linking)
dc.identifier.doi10.1200/JCO.2006.07.3569
dc.identifier.pmid17404369
dc.identifier.urihttp://hdl.handle.net/20.500.14038/47962
dc.description<p>This study was supported in part by Grant CA-29511 from the National Cancer Institute for the IROC Rhode Island (QARC), a quality assurance vehicle and data management service for diagnostic imaging and radiation oncology for the National Cancer Institute Clinical Trials Program. QARC is a research program within the University of Massachusetts Medical School led by Dr. Thomas (TJ) FitzGerald of the Department of Radiation Oncology.</p>
dc.description.abstractPURPOSE: Standard therapy for unresectable stage III non-small-cell lung cancer includes concomitant chemoradiotherapy. In Cancer and Leukemia Group B 39801, we evaluated whether induction chemotherapy before concurrent chemoradiotherapy would result in improved survival. PATIENTS AND METHODS: Between July 1998 and May 2002, 366 patients were randomly assigned to arm A, which involved immediate concurrent chemoradiotherapy with carboplatin area under the concentration-time curve (AUC) of 2 and paclitaxel 50 mg/m2 given weekly during 66 Gy of chest radiotherapy, or arm B, which involved two cycles of carboplatin AUC 6 and paclitaxel 200 mg/m2 administered every 21 days followed by identical chemoradiotherapy. The accrual goal was 360 patients. RESULTS: Thirty-four percent of patients were female, 66% were male, and the median age was 63 years. Grade 3 or 4 toxicities during induction chemotherapy on arm B consisted mainly of neutropenia (18% and 20%, respectively). During concurrent chemoradiotherapy, there was no difference in severity of in-field toxicities of esophagitis (grade 3 and 4 were, respectively, 30% and 2% for arm A v 28% and 8% for arm B) and dyspnea (grade 3 and 4 were, respectively, 11% and 3% for arm A v 15% and 4% for arm B). Survival differences were not statistically significant (P = .3), with a median survival on arm A of 12 months (95% CI, 10 to 16 months) versus 14 months (95% CI, 11 to 16 months) on arm B and a 2-year survival of 29% (95% CI, 22% to 35%) and 31% (95% CI, 25% to 38%). Age, weight loss before therapy, and performance status were statistically significant predictive factors. CONCLUSION: The addition of induction chemotherapy to concurrent chemoradiotherapy added toxicity and provided no survival benefit over concurrent chemoradiotherapy alone. The median survival achieved in each of the treatment groups is low, and the routine use of weekly carboplatin and paclitaxel with simultaneous radiotherapy should be re-examined.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=17404369&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://dx.doi.org/10.1200/JCO.2006.07.3569
dc.subjectAdult
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectAntineoplastic Combined Chemotherapy Protocols
dc.subjectArea Under Curve
dc.subjectCarboplatin
dc.subjectCarcinoma, Non-Small-Cell Lung
dc.subjectChemotherapy, Adjuvant
dc.subjectCombined Modality Therapy
dc.subjectFemale
dc.subjectHumans
dc.subjectLung Neoplasms
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectPaclitaxel
dc.subjectSurvival Analysis
dc.subjectNeoplasms
dc.subjectOncology
dc.subjectRadiology
dc.subjectTherapeutics
dc.titleInduction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B
dc.typeJournal Article
dc.source.journaltitleJournal of clinical oncology : official journal of the American Society of Clinical Oncology
dc.source.volume25
dc.source.issue13
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/radiationoncology_pubs/70
dc.identifier.contextkey7078874
html.description.abstract<p>PURPOSE: Standard therapy for unresectable stage III non-small-cell lung cancer includes concomitant chemoradiotherapy. In Cancer and Leukemia Group B 39801, we evaluated whether induction chemotherapy before concurrent chemoradiotherapy would result in improved survival.</p> <p>PATIENTS AND METHODS: Between July 1998 and May 2002, 366 patients were randomly assigned to arm A, which involved immediate concurrent chemoradiotherapy with carboplatin area under the concentration-time curve (AUC) of 2 and paclitaxel 50 mg/m2 given weekly during 66 Gy of chest radiotherapy, or arm B, which involved two cycles of carboplatin AUC 6 and paclitaxel 200 mg/m2 administered every 21 days followed by identical chemoradiotherapy. The accrual goal was 360 patients.</p> <p>RESULTS: Thirty-four percent of patients were female, 66% were male, and the median age was 63 years. Grade 3 or 4 toxicities during induction chemotherapy on arm B consisted mainly of neutropenia (18% and 20%, respectively). During concurrent chemoradiotherapy, there was no difference in severity of in-field toxicities of esophagitis (grade 3 and 4 were, respectively, 30% and 2% for arm A v 28% and 8% for arm B) and dyspnea (grade 3 and 4 were, respectively, 11% and 3% for arm A v 15% and 4% for arm B). Survival differences were not statistically significant (P = .3), with a median survival on arm A of 12 months (95% CI, 10 to 16 months) versus 14 months (95% CI, 11 to 16 months) on arm B and a 2-year survival of 29% (95% CI, 22% to 35%) and 31% (95% CI, 25% to 38%). Age, weight loss before therapy, and performance status were statistically significant predictive factors.</p> <p>CONCLUSION: The addition of induction chemotherapy to concurrent chemoradiotherapy added toxicity and provided no survival benefit over concurrent chemoradiotherapy alone. The median survival achieved in each of the treatment groups is low, and the routine use of weekly carboplatin and paclitaxel with simultaneous radiotherapy should be re-examined.</p>
dc.identifier.submissionpathradiationoncology_pubs/70
dc.contributor.departmentQuality Assurance Review Center
dc.contributor.departmentDepartment of Radiation Oncology
dc.source.pages1698-704


This item appears in the following Collection(s)

Show simple item record